This is rare but I've seen it twice last year! One with melanoma on nivolumab and one with lung cancer on pembrolizumab (both cases in deep remission), both with difficult-to-control multiple myeloma who qualify for a bispecific antibody like teclistamab. Would you be willing to use PD-1 inhibition and BCMAxCD3 targeting together?